Although targeting TP53-mutated cancers is challenging, several tumour-specific clinical trials are currently active for TP53-mutated ovarian cancer (NCT02272790 and NCT01164995), both of which assess the efficacy of combination treatment with Wee-1 kinase inhibitors and chemotherapy. This evidence concerns the gene TP53 and ovarian carcinoma.